Sensata Technologies is a global industrial technology company and leading provider of sensors, sensor-rich solutions and electrical protection devices across multiple industries including automotive, clean energy, industrials and aerospace

Providing strategic, financial, and operational support to companies in the life sciences industries. Primarily focused on assisting companies with fundraising to ensure appropriate growth capital and with operational and commercial activities to prepare for and support revenue growth.

ViewRay, Inc is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.

Tarveda Therapeutics is a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with various solid tumor malignancies. Our strategy includes developing our own proprietary Pentarin miniature conjugates to enhance the effectiveness of promising anti-cancer payloads that have struggled without their selective targeting to solid tumors. while minimizing exposure of healthy tissue to the payloads.

Avedro is a publicly traded pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction. Avedro is committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety.In 2016, the FDA approved Photrexa® Viscous (riboflavin 5′-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5′-phosphate ophthalmic solution) and the KXL® system for corneal cross-linking for patients suffering from progressive keratoconus and corneal ectasia following refractive surgery. Cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa eye drops and ultra-violet (UV) light. The approvals offer an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of these sight-threatening diseases.

Insulet Corp (NASDAQ: PODD) is a fast growing innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion.

Acquired by Marchex

CFO of Digitas through sale to Publicis Groupe in early 2007

Boston office